Atomic AI, a San Francisco, CA-based biotechnology company combining machine learning with structural biology to unlock RNA drug discovery, raised $35M in Series A funding.
The round was led by Playground Global, with participation from 8VC, Factory HQ, Greylock, NotBoring, AME Cloud Ventures, Nat Friedman, Doug Mohr, Neal Khosla, and Patrick Hsu.
The company intends to use the funds to accelerate growth, expand operations and its business reach.
Led by CEO Raphael Townshend, Atomic AI is a biotechnology company whose proprietary R&D platform leverages learning foundation models integrated into a virtuous cycle with purpose-designed, in-house wet-lab assays, to discover and design proprietary 3D RNA structural datasets. Its AI’s proprietary AI-driven 3D RNA structure engine generates RNA structural datasets, integrating machine learning foundation models with large-scale in-house experimental wet-lab biology to enable the world of RNA drug discovery. In particular, the technology can discover structured, ligandable RNA motifs at speed and accuracy. Beyond RNA-targeted molecules, the integrated platform will also enable the design of RNA-based medicines and RNA tools.
The company previously raised a $7M seed round led by 8VC and joined by Greylock, Factory HQ, AME Cloud Ventures, AIX Ventures, Xu Ventures, Doug Mohr, Antheia, Inc. CEO Dr. Christina Smolke, and Stanford Bioengineering professor Drew Endy.